Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vanucizumab, a pioneering bispecific IgG1-like monoclonal antibody, concurrently inhibits the interaction of VEGF-A and angiopoietin-2 (Ang-2) with their respective receptors, exerting antiangiogenic and anticancer properties [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Vanucizumab, a pioneering bispecific IgG1-like monoclonal antibody, concurrently inhibits the interaction of VEGF-A and angiopoietin-2 (Ang-2) with their respective receptors, exerting antiangiogenic and anticancer properties [1]. |
Molecular Weight | N/A |
CAS No. | 1448221-05-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Vanucizumab 1448221-05-3 inhibitor inhibit